Sort
10,829 grants matching “car t”
Innovative Physical Activity Interventions for Overweight Latinos
$667,226Abby C King · Stanford University · R01 · FY2015 · DK
Improved Chimeric Antigen Receptor Therapies B-cell Malignancies
$667,197James Kochenderfer · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Development and validation of an autologous mouse model for the study of immune interactions with glioblastoma
$667,171Zev Ari Binder · University Of Pennsylvania · R37 · FY2025 · CA
The Virtual Fitness Buddy Ecosystem: Using Digital Technology to Promote and Sustain Moderate-to-Vigorous Intensity Physical Activity in Children
$667,124Sun Joo Joo Ahn · University Of Georgia · R01 · FY2019 · HL
Improving clinical speech remediation with ultrasound technology
$666,862Doug H Whalen · Cuny Graduate Sch And Univ Ctr · R01 · FY2018 · DC
Gamma delta T cell based melanoma therapies
$666,701Xiaowei Xu · University Of Pennsylvania · R01 · FY2022 · CA
Collaborative Research: DMREF: NSF-NSERC: Structural Alloys for Fatigue Endurance (SAFE)
$666,664John J Lewandowski · Case Western Reserve University · · FY2025 · MPS
Collaborative Research: DMREF: NSF-NSERC: Structural Alloys for Fatigue Endurance (SAFE)
$666,664Anthony D Rollett · Carnegie Mellon University · · FY2025 · MPS
Collaborative Research: DMREF: NSF-NSERC: Structural Alloys for Fatigue Endurance (SAFE)
$666,664Kaushik Bhattacharya · California Institute Of Technology · · FY2025 · MPS
Massive single cell proteomics for cancer biology
$666,640Ljiljana Pasa-Tolic · Battelle Pacific Northwest Laboratories · R01 · FY2022 · CA
Goals for Adherence with Low-cost Incentives (GOALS)
$666,473Sebastian Linnemayr · Rand Corporation · R01 · FY2022 · HD
Combination antigen sensing engineered T cell for precise recognition and enhanced elimination of solid tumors
$666,268Kole T Roybal · University Of California, San Francisco · R01 · FY2025 · CA
Cancer prevention through neural and geospatial examination of tobacco marketing effects in smokers
$666,189Emily Falk · University Of Pennsylvania · R01 · FY2019 · CA
Combination antigen sensing engineered T cell for precise recognition and enhanced elimination of solid tumors
$666,104Kole T Roybal · University Of California, San Francisco · R01 · FY2023 · CA
Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma
$665,841Christine Brown · Beckman Research Institute/City Of Hope · R01 · FY2021 · CA
Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma
$665,839Christine Brown · Beckman Research Institute/City Of Hope · R01 · FY2019 · CA
Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma
$665,839Christine Brown · Beckman Research Institute/City Of Hope · R01 · FY2020 · CA
Fast and Accurate Cardiovascular MRI with Hyper 4D-Flow
$665,286Daniel B Ennis · Stanford University · R01 · FY2024 · HL
The Impact of a Changing Health Care Delivery System on the Quality of Oncology Care
$665,218Nancy L Keating · Harvard Medical School · R01 · FY2024 · CA
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma
$665,000Juan Fernando Vera · Marker Therapeutics, Inc. · R44 · FY2025 · CA
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma
$665,000Juan Fernando Vera · Marker Therapeutics, Inc. · R44 · FY2024 · CA
Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant
$664,838Juan Fernando Vera · Marker Therapeutics, Inc. · R44 · FY2023 · CA
Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant
$664,838Juan Fernando Vera · Marker Therapeutics, Inc. · R44 · FY2024 · CA
Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant
$664,838Juan Fernando Vera · Marker Therapeutics, Inc. · R44 · FY2025 · CA
The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy
$664,834Jennifer M Munson · Virginia Polytechnic Inst And St Univ · R01 · FY2023 · NS